Point72 Asset Management
ENGN icon

Point72 Asset Management’s enGene Therapeutics ENGN Stock Holding History

Point72 Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Sell
173,391
-388,406
-69% -$3.46M ﹤0.01% 2658
2025
Q4 		$5.07M Sell
561,797
-646,602
-54% -$5.18M 0.01% 1840
2025
Q3 		$8.25M Buy
1,208,399
+100
+0% +$456 0.01% 876
2025
Q2 		$4.4M Sell
1,208,299
-32,889
-3% -$123K 0.01% 1019
2025
Q1 		$5.56M Buy
1,241,188
+16,391
+1% +$102K 0.01% 888
2024
Q4 		$8.14M Buy
1,224,797
+561,797
+85% +$4.36M 0.02% 761
2024
Q3 		$4.38M Buy
663,000
+619,100
+1,410% +$4.61M 0.01% 919
2024
Q2 		$414K Sell
43,900
-138,686
-76% -$1.78M ﹤0.01% 1484
2024
Q1 		$3.09M Buy
+182,586
New +$2.23M 0.01% 1120

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Point72 Asset Management's ENGN Position: Q1 2026 in Review

Point72 Asset Management reduced its enGene Therapeutics (ENGN) stake by 69% in Q1 2026, selling an estimated $3.46M and leaving 173,391 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

Point72 Asset Management first reported a position in ENGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $8.25M in Q3 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Point72 Asset Management held 173,391 shares of enGene Therapeutics worth $1.18M as of Q1 2026.
  • Point72 Asset Management sold 388,406 enGene Therapeutics shares in Q1 2026, an estimated $3.46M.
  • enGene Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2658 holding.
  • Point72 Asset Management first reported a position in enGene Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Point72 Asset Management's enGene Therapeutics position peaked at $8.25M in Q3 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.